Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02830152

Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH) in patients with non-valvular atrial fibrillation (NVAF) poses a particular dilemma for thromboprophylaxis. Left atrial appendage occlusion (LAAO) is a non-pharmacological approach to prevent cardiac embolism in NVAF. The risk-benefit ratio of LAAO in patients with NVAF after ICH is unknown. The aim of STROKECLOSE is to assess the effect of LAAO to reduce the incidence stroke, bleeding and cardiovascular mortality in patients with NVAF and prior ICH.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebral Hemorrhage Cerebrovascular Disorders Heart Diseases Hemorrhage Intracerebral Hemorrhage Intracranial Hemorrhages Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aarhus University Hospital, Aarhus, Denmark

Loading trial locations.

About this study

Methods/design: A multicenter prospective randomized open-label clinical trial with blinded outcome evaluation (PROBE design) and blinded safety outcome assessment. The active comparison LAAO is tested against medical therapy in a 2:1 stratified randomization.

Study population: Patients should have had an ICH within 12 months prior to enrollment and have NVAF with increased risk of stroke or systemic embolism, as indicated by a CHA2DS2VASc score >2. In total 750 patients will be included. Active enrollment ensues over 3 years followed by 5 years follow-up and a long-term follow-up at 10 years.

Intervention and control: The intervention group will be treated by LAAO, using the Amplatzer Amulet device. Implantation requires a catheterization procedure using venous access and transseptal puncture and is guided by angiography, fluoroscopy and transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes aspirin (ASA) therapy for at least 6 months, with or without clopidogrel for the first 45 days after implantation. The control group will receive medical therapy, delivered according to national standards and guidelines at the treating physicians' discretion. This may include oral anticoagulation (OAC) (vitamin-K antagonists, VKA), non-VKA OAC, antiplatelet therapy or no antithrombotic therapy at all.

Main study outcomes: The primary outcome is the composite endpoint of stroke (ischemic and hemorrhagic), systemic embolism, life-threatening or major bleeding and all-cause mortality, assessed over at least two years. Secondary outcome examines various early and late safety outcome parameters.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of paroxysmal, persistent or long-standing NVAF with CHA2DS2VASc score >2.
  • Clinical and CT/MRI evidence of ICH within 12 months but not less than 4 weeks prior to enrollment.
  • Age > 18 years.
  • Signed informed consent.

Exclusion criteria

  • ICH secondary to vascular malformation or tumors
  • Estimated life expectancy of less than 1 year at eligibility assessment
  • mRS > 3 at enrollment
  • Prior surgical LAA excision
  • Planned combined interventional procedures at the time of enrollment

Treatment and study plan

LAAO

Device

The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.

Other names: AMPLATZER™ Amulet™ (St. Jude Medical)

Medical Therapy

Drug

Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.

Other names: Antiplatelet Therapy

Primary outcomes

  1. Composite endpoint of stroke (ischemic or hemorrhagic), systemic embolism, life-threatening or major bleeding and all-cause mortality

    Time frame: up to 5 years after randomization

    This endpoint will be assessed in patients with paroxysmal, persistent or long-standing NVAF and with ICH within 6 months prior to enrollment.

    The effect of LAAO will be compared to medical therapy at the treating physician's discretion as a control.

Secondary outcomes

  1. Number of participants with a device-related complication

    Time frame: up to 45 days after randomization

    A complication related to the presence of the device. Device-related complications include:

    • Device embolization
    • Device erosion
    • Clinically significant device interference with surrounding structures. This includes structures at the implant location (circumflex coronary artery, mitral valve, pulmonary artery, pulmonary vein) or cardiovascular structures in the vicinity of the location to which the device migrated (if applicable).
    • Device thrombus
    • Device fracture
    • Device infection/endocarditis/pericarditis
    • Device perforation/laceration
    • Device allergy

  2. Number of Participants with a device success

    Time frame: up to 45 days after randomization

    Device deployed and implanted in correct position.

  3. Number of Participants with a Technical success

    Time frame: up to 45 days after randomization

    Exclusion of the left atrial appendage (LAA) achieved without device-related complications and no leak >5 mm on color Doppler TEE.

  4. Number of Participants with a Procedural success

    Time frame: up to 45 days after randomization

    Technical success and no procedure-related complications, except uncomplicated device embolization (i.e. device embolization resolved by percutaneous retrieval during the procedure without surgical intervention or damage to surrounding cardiovascular structures).

  5. Number of Participants with Significant peridevice leak

    Time frame: up to 45 days after randomization

    Consistent with the definition of technical success, a significant peridevice leak is defined as a leak shown as a jet >5 mm on color Doppler TEE.

  6. Compare the functional status prior to and post treatment

    Time frame: 24 months after randomization

    The Modified Rankin Scale (mRS) will be used for measuring the Functional status.

  7. Compare the cognitive status prior to and post treatment

    Time frame: 24 months after randomization

    The cognitive status will be assessed by using Montreal Cognitive Assessment (MOCA) and Mini-mental state examination (MMSE)

  8. Compare the neurological status prior to and post treatment

    Time frame: 24 months after randomization

    The National Institutes of Health Stroke Scale (NIHSS) is used to assess the neurological status

  9. Compare the quality of life prior to and post treatment by using EuroQol

    Time frame: 24 months after randomization

    EuroQol assesses health status in terms of five dimension: mobility (walking about); looking after myself; doing usual activities (e.g., going to school, hobbies, sports, playing, doing things with family and friends); having pain or discomfort; and feeling worried, sad, or unhappy. The levels for the dimensions are: 'none/no problems', 'some (problems)', and 'a lot (of problems)'. Higher score represents more problems.

  10. Late safety outcome parameters of LAAO and Medical therapy

    Time frame: up to 10 years after randomization

    Stroke (ischemic or hemorrhagic), systemic embolism, bleeding, all-cause mortality, intracranial hemorrhage, cardiovascular mortality and unplanned hospitalization will be evaluated

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Abbott Medical Devices

Registry information

Official study title

Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage: A Multicenter Randomized Clinical Trial

Important dates

Study start
2017
Primary completion
2027
Study completion
2028
First posted
Jul 12, 2016
Registry last updated
Jun 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.